Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2011

Published: August 2011
No. of Pages: 87
   

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2011


Summary


GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q2 2011. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.


GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and primary and secondary research.


Scope


- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.


Reasons to buy


- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2011

1 Table of contents
1 Table of contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Pharmaceutical & Healthcare, Global, Deal Summary, Q2 2011 9
2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, Q2 2011 9
2.2 Pharmaceutical & Healthcare, Global, by Type, Number of Deals and Deal Values, Q2 2011 11
2.3 Pharmaceutical & Healthcare, Global, Top Deals, Q2 2011 12
2.3.1 Takeda Pharmaceutical To Acquire Nycomed International 12
2.3.2 Teva Pharmaceutical To Acquire Cephalon 12
2.3.3 Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes For $4.4 Billion 12
2.3.4 Ashland To Acquire International Specialty Products 13
2.3.5 Amgen Completes Public Offering Of Senior Unsecured Notes For $3 Billion 13
3 Pharmaceutical & Healthcare, Global, Deals Summary, by Type 14
3.1 Pharmaceutical & Healthcare, Global, M&A, Q2 2011 14
3.1.1 Top M&A Deals in Q2 2011 15
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q2 2010 - Q2 2011 16
3.2 Pharmaceutical & Healthcare, Global, Equity Offering Deals, Q2 2011 17
3.2.1 Top Initial Public Offerings in Q2 2011 18
3.2.2 Top Secondary Offerings in Q2 2011 18
3.2.3 Top PIPE Deals in Q2 2011 18
3.2.4 Pharmaceutical & Healthcare, Global, Top IPOs Share Performance, Q2 2010–Q2 2011 19
3.2.5 Pharmaceutical & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q2 2010 – Q2 2011 20
3.3 Pharmaceutical & Healthcare, Global, Debt Offering Deals, Q2 2011 21
3.3.1 Top Public Debt Offerings in Q2 2011 22
3.3.2 Top Private Debt Placements in Q2 2011 22
3.3.3 Pharmaceutical & Healthcare, Global, Debt Offering Deals, by Therapy Area, Q2 2010 - Q2 2011 23
3.4 Pharmaceutical & Healthcare, Global, Venture Capital Deals, Q2 2011 24
3.4.1 Top Venture Financing Deals in Q2 2011 25
3.4.2 Pharmaceutical & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2011 26
3.4.3 Pharmaceutical & Healthcare, Global, Venture Capital, by Therapy Area, Q2 2010 - Q2 2011 27
3.4.4 Pharmaceutical & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 28
3.4.5 Pharmaceutical & Healthcare, Global, Top VC Backed Companies, Last One Year 29
3.5 Pharmaceutical & Healthcare, Global, Private Equity Deals, Q2 2011 30
3.5.1 Top Private Equity Deals in Q2 2011 31
3.5.2 Pharmaceutical & Healthcare, Global, Private Equity Deals, by Therapy Area, Q2 2010 - Q2 2011 32
4 Pharmaceutical & Healthcare, Global, Partnership Deals, Q2 2011 33
4.1 Pharmaceutical & Healthcare, Global, Partnership Deals, Q2 2011 33
4.2 Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2010 - Q2 2011 34
4.3 Pharmaceutical & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2011 35
4.3.1 Pharmaceutical & Healthcare, Global, Top Partnership Deals, by Deal Values, Q2 2011 36
4.3.2 Pharmaceutical & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2011 36
4.3.3 Pharmaceutical & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q2 2011 37
4.4 Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2010 - Q2 2011 38
4.5 Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 39
4.6 Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2010 - Q2 2011 40
5 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2011 41
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2011 41
5.2 Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2010 - Q2 2011 42
5.2.1 Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q2 2011 43
5.2.2 Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q2 2011 43
5.2.3 Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q2 2011 44
5.2.4 Pharmaceutical & Healthcare, Global, Licensing Agreements with Equity Investment, Q2 2010 – Q2 2011 44
5.3 Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2010 - Q2 2011 45
5.4 Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q2 2010 - Q2 2011 46
5.5 Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2010 - Q2 2011 47
5.6 Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q2 2010 - Q2 2011 48
6 Pharmaceutical & Healthcare, Global, M&A Financial Analysis 49
6.1 Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q2 2010 - Q2 2011 49
6.2 Pharmaceutical & Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q2 2010 - Q2 2011 50
6.3 Pharmaceutical & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2010 - Q2 2011 51
6.4 Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2010 - Q2 2011 52
6.5 Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q2 2010 - Q2 2011 53
6.6 Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q2 2010 - Q2 2011 54
6.7 Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2010 - Q2 2011 55
7 Pharmaceutical & Healthcare, Global, Deal Summary by Therapy Area 56
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2011 56
7.1.1 Oncology – Deals of the Quarter 57
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2011 58
7.2.1 Central Nervous System – Deals of the Quarter 59
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2011 60
7.3.1 Infectious Disease – Deals of the Quarter 61
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2011 62
7.4.1 Immunology – Deals of the Quarter 63
7.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2011 64
7.5.1 Cardiovascular – Deals of the Quarter 65
7.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2011 66
7.6.1 Metabolic Disorders – Deals of the Quarter 67
7.7 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2011 68
7.7.1 Respiratory – Deals of the Quarter 69
7.8 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2011 70
7.8.1 Gastrointestinal – Deals of the Quarter 71
7.9 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2011 72
7.9.1 Dermatology – Deals of the Quarter 73
7.10 Pharmaceuticals & Healthcare, Global, Musculoskeletal Deals, Q2 2011 74
7.10.1 Musculoskeletal – Deals of the Quarter 75
8 Deal Summary by Geography 76
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q2 2011 76
8.1.1 North America – Deals of the Quarter 77
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q2 2011 78
8.2.1 Europe – Deals of the Quarter 79
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q2 2011 80
8.3.1 Asia-Pacific – Deals of the Quarter 81
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q2 2011 82
8.4.1 Rest of the World – Deals of the Quarter 83
9 Pharmaceuticals & Healthcare, Global, Top Advisors 84
9.1 Pharmaceutical & Healthcare, Global Top Financial Advisors, M&A, Last One Year 84
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 85
10 Further Information 86
10.1 Methodology 86
10.2 About GlobalData 86
10.3 Contact Us 87
10.4 Disclosure information 87
10.5 Disclaimer 87

Published By: GlobalData
Product Code: GlobalData19753


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100